oral semaglutide news HUGE in the GLP-1 space! Orforglipron has outperformed in the ACHIEVE-3 clinical trial in patients with type 2 diabetes. Comment your thoughts below! ⬇️ A network meta-analysis backed weight-loss

De hecho, los anlisis de mediacin realizados sugirieron que solo aproximadamente el 25% del beneficio sobre los resultados renales puede estar mediado por un mejor control glucmico y un 9-22% por los cambios sobre la presin arterial92,106, lo que sugiere el papel de mecanismos directos: reduccin de la hiperfiltracin, del estrs oxidativo y de la inflamacin, efectos antifibrticos, mejora de la disfuncin endotelial y/o posible reduccin de niveles de angiotensina ii52,54,107109

Read more: To view or add a comment, sign in Pharmaceutical Guidelines Series Day 11 Todays topic -Pre-Clinical Studies a crucial stage in drug development conducted before human trials

Additionally, GLP-1 compounds offer cardiovascular and metabolic benefits beyond weight reduction, including improved blood sugar control and reduced heart disease risk in patients with type 2 diabetes

Consulting with a knowledgeable healthcare provider or peptide specialist can provide valuable guidance tailored to your individual needs